Small Cap Feast
Small Cap Feast – 13 August 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Rumours and Speculation
SDIC Power Holdings China’s state-backed energy firm has received government approval to issue 10% of its share capital as Global Depositary Receipts (GDRs) on the London Stock Exchange
e-Therapeutics plc (ETX) 2.85p £6.72m
e-therapeutics plc (AIM: ETX, “e-therapeutics”) is pleased to announce an agreement to work with a global, top five pharmaceutical company, on a project in a specific area of biology associated with neurodegenerative diseases.
Neurodegeneration occurs when there is progressive loss of structure or function of neurons and can lead to a number of debilitating diseases such as Parkinson’s, Alzheimer’s and Huntington’s.1 There are currently over one billion people globally affected by these conditions.2
Under the 12-month agreement, e-therapeutics will use its proprietary Network-Driven Drug Discovery (“NDD”) approach to identify novel disease pathways and small molecules, both of which have the potential to modulate the biology of interest. As part of the project, the company will test the compounds resulting from e-therapeutics’ NDD platform in its in-house assays.
ADVFN PLC (AFN) 28.50p £7.33m
ADVFN (LSE:AFN) has licensed foreign rights to Harriman House for a number of titles from its financial books division.
Under the agreement Harriman House, the UK’s leading independent publisher of finance, trading and investment books, will act as agent, offering the rights of the ADVFN Books(https://www.advfnbooks.com/) titles to its extensive world-wide network. Harriman House will also undertake the translations. This will facilitate residual income for ADVFN.
ADVFN Books is home to a number of acclaimed titles and has a stable of writers who are experts in the fields of finance and investing. The deal will initially license foreign rights for three titles: A Beginner’s Guide to Value Investing by Clem Chambers, Trade Financial Markets Like the Pros and The Complete Guide to Successful Financial Markets Trading both by Simon Watkins, with the prospect of more titles being licensed in the near future.
HydroDec Group plc (HYR) 51p £14.47m
Hydrodec Group plc (AIM: HYR), the clean-tech industrial oil re-refining group, announced the disposal of its Australian plant and equipment, and an agreement to licence certain other rights in respect of those assets, to Greenbottle Re-refining (UK) Limited (“Greenbottle”).
The plant and equipment has been sold to Greenbottle for a gross consideration of A$2m in cash;
The Company is expected to receive a net figure of A$1.7 million after estimated decommissioning and transportation costs;
In addition, the Group has the right to receive a royalty from Greenbottle, for an initial period of 8 years, further details are below; and
The anticipated net proceeds will be used to satisfy outstanding liabilities of the Australian operating entities and A61 arterial road.
Eurasia Mining PLC (EUA) 0.47p £11.45m
Eurasia Mining PLC, the palladium, platinum, rhodium and gold producing company, provides an update on developments at the Monchetundra Project in the first half of 2019. Eurasia is developing its Monchetundra Project towards production following the issue of a mining permit for the circa 2Moz (2PGE + Gold) palladium dominated deposit (as announced on 20 November 2018).
A Engineering, Procurement and Construction (EPC) contract, with an associated mine finance package has been signed with Chinese company Sinosteel. Eurasia and its contractors are making progress on the production preparation activities stipulated by the EPC as TGK’s (Eurasia’s 80% subsidiary) responsibilities to initiate the payments from Sinosteel to TGK under the subcontracted works for the total amount of $50m, $26.5m of which will be paid by TGK to Sinosteel, as TGK’s contribution equity contribution to the EPC (the remaining $149.5m is a 10 year loan facility at 6mLIBOR + 3.5%).
Bango PLC (BGO) 134.50p £86.74m
Bango (AIM: BGO), the mobile commerce company, and Spotify, have entered into a business partnership to increase access to the world’s most popular audio streaming subscription service. By partnering with Bango, Spotify makes its streaming service available for operators all over the world to bundle with mobile and fixed subscription plans allowing millions more fans to enjoy their favorite artists.
This partnership will enable millions of customers to select a Spotify subscription bundled with their mobile plan, or as a bolt-on. Bango Resale technology delivers a single, powerful solution that will enable Spotify to reach new customers, and ensures active customers enjoy seamless access to their services. In addition, Bango data insights supports with targeting specific customers with new offers to generate higher customer adoption.
Cluff Natural Res (CLNR) 1.48p £20.74m
Cluff Natural Resources Plc, the AIM quoted natural resources investing company with a high impact exploration and appraisal portfolio focused on the Southern and Central North Sea, announced that it has received the required regulatory consent from the Oil and Gas Authority (‘OGA’) in relation to the farm-out of Licence P2437 to Shell U.K. Limited (“Shell”) and that the farm out has been completed.
Audioboom Group PLC (BOOM) 202.50p £28.36m
Audioboom (AIM: BOOM), the leading global podcast company, announces that it is the headline sponsor of the 2019 Podcast Movement conference – the world’s biggest podcast event. For the third year running, Audioboom is the lead sponsor of the prestigious event, which is attended by aspiring podcasters, industry representatives, host talent, podcasting professionals and aspiring producers from around the world.
Podcast Movement runs from 13-16 August 2019 in Orlando, Florida and provides a range of forums, hosting the biggest names in podcasting, panel discussions and networking events as well as education and training for podcasters and show hosts.
Starcom PLC (STAR) 1.10p £4.14m
Starcom (AIM: STAR) which specialises in the development of wireless solutions for the remote tracking, monitoring and protection of a variety of assets, announces its unaudited interim results for the six months ended 30 June 2019 (the “Period”).
Revenues for the Period remained stable at $3.1m (H1 2018: $3.1m)
Gross profits were $1.26m (H1 2018: $1.23m)
Gross margin increased to 41% (H1 2018 40%)
EBITDA increased to $75,000 (H1 2018: $40,000 EBITDA loss)
Recurring Software as a Service (“SaaS”) revenues were $900,000 (H1 2018: $890,000)
Lokies, Starcom’s new intelligent padlock, has been launched
essensys plc (ESYS) 3.65p £37.71m
essensys plc (AIM:ESYS), the leading global provider of mission critical software-as-a-service (SaaS) platforms and on-demand cloud services to the flexible workspace industry is pleased to announce an unaudited pre-close trading update for the financial year ended 31 July 2019.
Iofina PLC (IOF) 22.10p £43.46m
Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, is pleased to announce the incorporation and launch of a subsidiary company IofinaEX Global Inc.
IofinaEX Global will specialise in the production of Hemp derived products in Central America and the Caribbean for export into the United States and internationally.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.